Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat.com 3 Stocks You'll Wish You Bought Before 2026Written by Chris Markoch. Published 12/3/2025. 
Key Points - These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
- Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
- Analysts stay optimistic, with price targets suggesting possible double- or triple-digit gains from current levels.
Many investors profited from the artificial intelligence (AI) trade in 2025, but several up-and-coming stocks in other sectors have also posted impressive gains this year. The three stocks in this article are still small-cap — the largest market cap is just over $4 billion — yet they've made strong moves and reinforced the idea that time in the market often beats trying to time the market. A growing number of investors are questioning how much of the market is now concentrated in just a handful of mega-cap stocks.
In a recent interview, a veteran investor discusses why this concentration matters, how he's structured his own portfolio to reduce reliance on Big Tech, and the framework he believes can deliver competitive returns with lower volatility across market cycles. Watch the full interview here Of course, if investors could see the future with absolute clarity, investing would be easy. The future is rarely clear, and a bullish outcome is not guaranteed. Still, the charts speak for themselves: investors who bought these stocks and held through rough stretches are seeing the benefits now. And these stocks may not be done moving higher. Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company that recently delivered positive data for its first-in-class PI3K/mTOR inhibitor targeting HR+/HER2- metastatic breast cancer. The company's pivotal Phase 3 VIKTORIA trial is underway, and some expect U.S. Food & Drug Administration (FDA) approval in 2026. Investors have been front-running those potential results, pushing CELC stock up more than 660%, with nearly all of the gains occurring since the end of July. At $99.30 as of this writing, the stock is within about 3% of its consensus price target. On Dec. 2, Jefferies raised its price target on the stock to $134 from $108. The biggest risk is the cost of commercialization. However, in its most recent earnings report, Celcuity showed a strengthened balance sheet with $455 million in cash, cash equivalents, and short-term investments — up about 72% year-over-year (YOY). Management believes that will be sufficient until commercialization begins. Fintech Disruptor Turning Revenue Growth Into Real Momentum At a time when many banks offer less to everyday consumers, it's easy to make the case for Dave Inc. (NASDAQ: DAVE), the Los Angeles-based fintech behind the Dave app. The Dave app provides affordable, transparent tools that help users — many living paycheck to paycheck — avoid overdraft fees, budget more effectively, and access short-term cash when needed. The company recently reported 64% YOY revenue growth and an 85% beat in adjusted earnings per share (EPS). DAVE stock is up 120% in 2025, and analysts see more upside. As of this writing the stock trades at $208.24, while the consensus price target is $304.25 — an implied upside of more than 46%. Some investors may balk at a forward price-to-earnings (P/E) ratio near 119x. But analysts forecast earnings growth of more than 117% over the next 12 months, which could help justify that valuation if the company hits those targets. Resale Retail Winner Riding a Massive Consumer Shift It's been another tough year for consumer staples stocks, but ThredUp Inc. (NASDAQ: TDUP) has been a notable exception. TDUP stock is up more than 430% in 2025, despite a roughly 29% sell-off in the three months ending Dec. 1. The company operates an online consignment marketplace, a natural fit as many consumers continue to stretch their budgets. The thrift and resale market was a $49 billion industry in 2024 and is expected to grow to $74 billion by 2029. TDUP is the smallest of the three stocks on this list, and short interest above 17% indicates active trading. That said, the company's Q3 report showed strong YOY revenue growth, a record in new-buyer acquisition, and a 37% YOY increase in orders. This could be a volatile, shorter-term trade, but ThredUp's core demographic — younger shoppers feeling budget pressure — suggests secular tailwinds remain. Analysts' consensus price target for TDUP is $12.50, implying about a 68% gain from its closing price on Dec. 1.
| 
